{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_9023788_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"172-059-128-055-080","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8676,"type":"PATENT","title":"New York University Patent Portforlio ","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":5145,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2015-11-12T00:15:20Z","updated":"2015-11-23T01:36:42Z","lastEventDate":"2015-11-23T01:36:42Z"},{"id":8877,"type":"PATENT","title":"New York Univ Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":15466,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8211,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners seperately = \"New York Univ\", \"New York University NOT \"state\" NOT \"city\" \", \"Univ New York\", \"NYU\".
Search Applicants and Owners seperately = \"New York Univ\", \"New York University NOT \"state\" NOT \"city\" \", \"Univ New York\", \"NYU\".
a) a prodrug or compound according to formula IIIc:\n\n
\n\nor a pharmaceutically acceptable salt, or solvate thereof; and stereoisomers, isotopic variants and tautomers thereof;\n
b) an additional α-adrenergic modulator; and\n
c) a carrier or adjuvant."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 1, wherein the prodrug or the compound does pass the blood-brain barrier."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 1, wherein the prodrug or the compound does pass the blood-brain barrier and is enzymatically cleaved within the brain to yield the active parent catecholamine."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 1, wherein the additional α-adrenergic modulator is selected from the group consisting of doxazosin, terazosin, labetalol, indoramin, phenoxybenzamine, tolazoline, and dihydroergotamine."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 1, wherein the additional α-adrenergic modulator is a modulator incapable of crossing the blood-brain barrier."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 1, wherein the additional α-adrenergic modulator is a modulator which does not enter the brain."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to any claim 1, wherein the additional α-adrenergic modulator is an α-adrenergic antagonist."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 1, wherein the additional α-adrenergic modulator is prazosin."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 1, wherein the additional α-adrenergic modulator is present at dosage levels equivalent to 10 to 100% of the dosage normally administered in a monotherapy regimen."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 1, wherein the additional α-adrenergic modulator is present at dosage levels equivalent to about 0.5 to about 2 mg of the dose."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 1, wherein the additional α-adrenergic modulator is present at dosage levels equivalent to about 0.5 to about 2 mg of the dose and is administered twice daily."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 1, wherein the carrier is a parenteral carrier."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 1, wherein the carrier is an oral carrier."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The pharmaceutical composition according to claim 1, wherein the carrier is a topical carrier."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating α-adrenergic mediated disease or condition in a mammal comprising the step of administering to said mammal a pharmaceutical composition according to claim 1."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 15, wherein the disease or condition is an anxiety disorder or a mood disorder."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating a disease selected from the group consisting of an anxiety disorder or a mood disorder in a mammal comprising the step of administering to said mammal a pharmaceutical composition according to claim 1."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 17 wherein the disease is an anxiety disorder."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 17 wherein the disease is a mood disorder."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 19 wherein the mood disorder is selected from the group consisting of dysthymia and major depression."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 17 wherein the administering results in a reduction in at least one clinical symptom of depression within one day."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 17 wherein the administering results in a reduction in at least one clinical symptom of depression within one week."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 17 wherein the administering results in a reduction in at least one clinical symptom of depression within one month."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 17 wherein the administering results in reducing a neural response in a stress response."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 17 wherein the administering results in increasing neural activity in one or more areas of the brain involved in motivated behavior."],"number":25,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}